For example, the selective estrogen receptor degrader fulvestrant is the first-in-class drug approved for the treatment of hormone receptor-positive, HER2-netagive, advanced stage breast cancer (McDonnell et al., 2015). Here, ESR1 is linked to breast carcinoma.